Dosing and Administration

Prolia is taken twice a year by subcutaneous injection1

Dosing Considerations

Down arrow
Injection Infographic
Prolia packshot with syringe and card
Administration of Prolia is to only be performed by an individual who has been adequately trained in injection techniques.
Please see the Product Monograph for complete dosing and administration information.
Storage and Injection

Prolia Dosing Considerations

No dose adjustment necessary in patients with renal impairment; however, adequate intake of calcium and vitamin D is important in patients with severe renal impairment or receiving dialysis. In clinical studies, patients with severe renal impairment (creatine clearance <30 mL/min) or receiving dialysis were at greater risk of developing hypocalcemia.1

Adequate intake of calcium and vitamin D is important in all Prolia patients.1

Pregnancy must be ruled out prior to administration of Prolia. Pregnancy testing should be preformed in all women of reproduction potential prior to Prolia administration. Based on findings in animals, PROLIA may cause fetal harm when administered to pregnant women.1

Pharmacodynamics of Prolia

Inhibition of bone remodeling is reversible upon discontinuation.1*

Patients treated with Prolia showed normal architecture and quality on histologic assessment and no evidence of mineralization defects, woven bone or marrow fibrosis.1

* Clinical significance has not been established.
Additional Resources
ProVital Icon

Find out more about the ProVital Patient Support Program

Provital patient
support program
Multiple vertebral fractures Icon
Multiple vertebral fractures

Find out more about multiple vertebral fractures following discontinuation of Prolia treatment MVF following Prolia discontinuation.

Safety logo

You are now leaving the website.

The linked sites are not under the control of Amgen, and Amgen is not responsible for the content available on the linked sites. Such links do not imply Amgen's endorsement of material on any other site, and Amgen disclaims all liability with regard to your access to such linked websites. Amgen provides links to other Internet sites as a convenience to users, and access to such linked sites is at your own risk.

Do you want to link to our other external sites and leave

You are now leaving the website. Please note that the information you are about to view may not comply with Canadian regulatory requirements. Marketing authorizations and availability of products may differ between Canada and other countries.


Do you want to link to another Amgen Canada site?

Yes, leave  

You are now leaving the website. Please note that these links are being provided as a convenience and for informational purposes only.